Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brexit

Set Alert for Brexit

Brexit Finally Here But Uncertainty Not Over For Biopharma

A free trade deal needs to be negotiated in record time and UK life sciences must face up to diverging from the EU.

Europe United Kingdom Brexit

UK Biotech Financing Holds Up Despite Woodford and Brexit

Neil Woodford’s fall from grace and Brexit dragged on an otherwise buoyant sector.

Biologics Commercial StartUps and SMEs

Latest From Brexit

UK To Seek Only Limited Regulatory Alignment With EU

Despite the life sciences industry’s call for continued alignment of medicines regulation with the EU from next year and for some sort of co-operation with the European Medicines Agency, it seems the UK government is prepared to make only small concessions.

United Kingdom Brexit

‘No Unified Patent Court For Us’, Says UK Government

The UK’s decision to pull out of Europe’s Unified Patent Court system throws the future of the whole project into doubt.

Europe United Kingdom

Back With A Bang: ‘Brexit Bill’ For UK’s Medical Devices Due For 2nd Reading On 2 March

Parliamentary debate next week on the post-Brexit regulatory adjustments ahead for the UK medical devices industry will coincide with the opening of post-Brexit EU trade talks by the UK government. After a period of nervous calm, Brexit will be back with a bang.

United Kingdom EU

Hunt On For New Chair Of UK Regulator

Whoever takes over as chair of the Medicines and Healthcare products Regulatory Agency will play a key role in its plans to deliver a program of “ambitious business change.”

United Kingdom Brexit

Hunt On For New Chair Of UK Regulator

Whoever takes over as chair of the Medicines and Healthcare products Regulatory Agency will play a key role in its plans to deliver a program of “ambitious business change.”

United Kingdom Brexit

Podcast: Living In China's Coronavirus Lockdown; Novartis and England's 'Public Health' Alliance; Biogen's Moment of Truth Approaches

Scrip's Brian Yang describes what life is like in China as the authorities battle to contain the coronavirus, and drug developers race to find vaccine and anti-virals against the new threat. Plus news on Novartis' bold initiative with England on inclisiran, and what lies ahead for Biogen and Alzheimer's treatment in 2020.

International Commercial

All About Value – Brexit Aside, UK Industry Sees Good Things Ahead For Healthtech Adoption

ABHI director of value and access Luella Trickett talks about the importance of real-world evidence in product development and value-based procurement in secondary care in the UK.

United Kingdom Market Access

UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System

At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.

United Kingdom Regulation

UK MHRA Looks Beyond Brexit Transition

Now that the UK has left the EU, the UK’s medicines regulator says it will use the rest of this year to work out how best to ensure continuity of drug regulation after the Brexit transition period ends on 31 December.

Brexit Regulation
See All
UsernamePublicRestriction

Register